Medicine and Dentistry
Inpatient
100%
Hepatocellular Carcinoma
100%
Erlotinib
100%
Epidermal Growth Factor Receptor
33%
Receptor Expression
25%
Diseases
16%
Malignant Neoplasm
16%
Female
16%
Overall Survival
16%
Combination Therapy
8%
Therapeutic Procedure
8%
Cancer Therapy
8%
Age
8%
Neoplasm
8%
Growth Factor
8%
Protein Tyrosine Kinase
8%
Progression Free Survival
8%
Tyrosine-Kinase Inhibitor
8%
Drug Dose Reduction
8%
Sex Ratio
8%
Liver Cirrhosis
8%
Systemic Therapy
8%
Response Evaluation Criteria in Solid Tumors
8%
Program Evaluation
8%
Nursing and Health Professions
Patient
100%
Liver Cell Carcinoma
100%
Child
33%
Epidermal Growth Factor Receptor
33%
Overall Survival
16%
Male
16%
Control
8%
Diseases
8%
Malignant Neoplasm
8%
Combination Therapy
8%
Disease Control
8%
Cancer Therapy
8%
National Health Organization
8%
Neoplasm
8%
Drug Dose Reduction
8%
Progression Free Survival
8%
Systemic Therapy
8%
Response Evaluation Criteria in Solid Tumors
8%
Protein Tyrosine Kinase Inhibitor
8%
Growth Factor
8%
Liver Cirrhosis
8%
Program Evaluation
8%
Pharmacology, Toxicology and Pharmaceutical Science
Liver Cell Carcinoma
100%
Erlotinib
100%
Epidermal Growth Factor Receptor
33%
Malignant Neoplasm
25%
Diseases
16%
Overall Survival
16%
Neoplasm
8%
Progression Free Survival
8%
Protein Tyrosine Kinase
8%
Protein Tyrosine Kinase Inhibitor
8%
Liver Cirrhosis
8%
Cancer Staging
8%
Growth Factor
8%